Xention Discovery

Xention is a biopharmaceutical company specializing in the discovery and development of small molecule drugs targeting ion channels. Based in Cambridge, UK, the company has developed a proprietary platform to identify modulators of ion channels for various therapeutic areas, with a primary focus on cardiovascular and inflammatory diseases. Its lead program, XEN-D0101, is a selective Kv1.5 channel blocker developed for the treatment of atrial fibrillation, which was notably partnered with Servier. Xention has also successfully spun out assets into separate entities like Ario Pharma and InCarda Therapeutics to advance specific indications such as chronic cough and inhaled cardiovascular therapies. The company's expertise in ion channel biology has led to the creation of a robust pipeline of candidates targeting Kv1.5, Kv1.3, and TRPV1 channels.